MarketCapExport financials
Acorda Therapeutics (ACOR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Acorda Therapeutics Financial Ratios 2023-2007 | ACOR
Brief overview of Acorda Therapeutics's multiples and efficiency
The comparison uses the five latest available annual observations between 2012 and 2018.
The valuation comparison uses P/E 488.86x (median 488.86x), EV/EBITDA 0.06x (median 9.45x), P/S 0.14x (median 0.15x). Ratios sit near their own comparison base, with an average deviation of -3.3% from five-year medians.
The inverse P/E implies an earnings yield of 0.2%. This is not a dividend yield, but current earnings relative to market price.
Returns on assets and capital are represented by ROE 160.1%, ROA -2.3%, ROCE 167.7%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.
A longer cycle, from -66.2 days to 116.7 days, indicates slower release of cash from operations.
Valuation takeaway
Acorda Therapeutics trades near its familiar ratio range. A new earnings or profitability trend is needed to change the view.
Annual Financial Ratios Acorda Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.1 | -0.2 | -0.2 | -0.5 | -0.4 | 488.9 | -32.1 | -160.8 | 843.7 | 580.5 | 430.7 | 44.1 | 195.2 | - | - | - | - |
P/S |
0.1 | 0.1 | 0.2 | 0.4 | 0.5 | 67.8 | 12.2 | 10.7 | 18.9 | 25.6 | 21.0 | 22.4 | 20.4 | - | - | - | - |
EPS |
-203.6 | -65.2 | -9.8 | -12.3 | -34.4 | 0.2 | -4.9 | -0.8 | 0.3 | 0.4 | 0.4 | 3.9 | 0.8 | -0.3 | -2.2 | - | - |
EV (Enterprise Value) |
-13.2 M | -23.9 M | -26 M | 378 M | 523 M | 5.08 B | 7.53 B | 6.09 B | 9.69 B | 10.6 B | 7.2 B | 6.97 B | 6.09 B | -34.6 M | -47.3 M | -29.6 M | -16.8 M |
EBITDA per Share |
-188 | -2.5 | -4.24 | -4.55 | -35 | 1.06 | -4.56 | -0.32 | 1.16 | 1.09 | 0.93 | 0.77 | 1.02 | -0.12 | -2.08 | - | - |
EV/EBITDA |
0.1 | 9.4 | 0.6 | -10.3 | -1.9 | 101.8 | -35.9 | -422.7 | 197.7 | 236.6 | 192.7 | 230.5 | 153.5 | 7.7 | 0.6 | 0.4 | - |
PEG |
-0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.23 | -0.13 | 7.47 | -4.54 | -2.82 | -0.82 | 0.02 | 0.09 | - | - | - | - |
P/B |
0.2 | 0.0 | 0.0 | 0.2 | 0.3 | 7.7 | 13.8 | 8.4 | 15.6 | 19.6 | 16.1 | 17.7 | 29.1 | - | - | - | - |
P/CF |
-1.2 | -0.7 | -0.5 | -0.9 | -0.8 | 31.1 | 73.7 | 187.8 | 49.5 | -4.2 | 49.0 | 29.5 | 90.1 | - | - | - | - |
ROE % |
160.08 | -70.41 | -68.78 | -41.85 | -87.82 | 1.57 | -42.95 | -5.21 | 1.83 | 3.27 | 3.73 | 40.15 | 14.91 | -7.78 | -61.12 | -35.89 | - |
ROA % |
-232.99 | -16.66 | -22.82 | -15.74 | -34.13 | 0.74 | -18.64 | -2.58 | 1.00 | 1.66 | 2.71 | 27.41 | 8.06 | -3.44 | -26.27 | - | - |
ROCE % |
167.74 | -37.75 | -52.30 | -15.76 | -43.69 | 3.32 | -22.09 | -3.01 | 3.31 | 3.77 | 5.95 | 5.49 | 12.00 | -5.57 | -59.17 | -35.45 | - |
Current Ratio |
- | - | - | 1.6 | 1.6 | 1.9 | 1.8 | 2.0 | 2.2 | 2.0 | 3.6 | 3.2 | 2.2 | - | - | - | - |
DSO |
48.3 | 47.5 | 52.6 | 50.4 | 43.2 | 276.7 | 41.5 | 29.4 | 23.6 | 28.6 | 31.0 | 29.3 | 28.2 | - | - | - | - |
DIO |
345.2 | 188.3 | 211.3 | 293.5 | 284.0 | 124.3 | 61.5 | 145.6 | 143.3 | 121.5 | 143.3 | 132.7 | 155.6 | - | - | - | - |
DPO |
276.8 | 124.3 | 102.9 | 209.2 | 393.4 | 142.5 | 89.0 | 69.9 | 67.0 | 91.9 | 98.5 | 153.1 | 117.3 | - | - | - | - |
Operating Cycle |
393.5 | 235.8 | 263.9 | 343.9 | 327.2 | 401.0 | 102.9 | 175.0 | 166.8 | 150.2 | 174.3 | 162.0 | 183.8 | - | - | - | - |
Cash Conversion Cycle |
116.7 | 111.6 | 161.0 | 134.8 | -66.2 | 258.5 | 13.9 | 105.1 | 99.8 | 58.3 | 75.8 | 8.9 | 66.5 | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Acorda Therapeutics
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-22.06 | -7.16 | -7.55 | -0.69 | - | -0.57 | -2.78 | -1.85 | - | -2.43 | -2.29 | -3.53 | - | 0.15 | -0.37 | -0.14 | 1.38 | -5.55 | -0.58 | -1 | 0.2 | -0.29 | 0.99 | -0.18 | -3.7 | -0.55 | -0.18 | -0.41 | -0.07 | -0.28 | -0.4 | -0.01 | 0.22 | 0.09 | 0.02 | -0.07 | 0.01 | 0.29 | 0.11 | 0.02 | 0.15 | 0.19 | 0.1 | -0.03 | 3.36 | 0.24 | 0.12 | 0.2 | 0.32 | 0.48 | -0.01 | -0.02 | 0.32 | - |
EBITDA per Share |
-15.1 | 17.1 | 9.82 | -0.15 | - | 0.81 | 0.18 | -0.62 | - | 0.22 | 0.15 | -2.14 | - | 0.98 | 0.23 | 0.08 | - | -4.94 | -0.18 | -0.81 | - | 0.79 | 1.4 | 0.08 | - | 0.33 | 0.31 | -0.21 | - | 0.23 | -0.09 | -0.3 | - | 0.87 | 0.31 | 0.06 | - | 0.64 | 0.36 | 0.13 | - | 0.4 | 0.29 | -0.03 | - | 0.34 | 0.18 | 0.25 | - | 611 | 79.5 | 0.04 | 0.42 | -0.1 |
ROE % |
-36.01 | -69.04 | -107.07 | -112.48 | -90.61 | -107.07 | -100.79 | -63.90 | -44.68 | -42.34 | -31.86 | -21.97 | -5.76 | 15.37 | -80.64 | -79.70 | -85.99 | -105.55 | -14.20 | -1.54 | 5.37 | -29.10 | -30.48 | -39.28 | -40.59 | -8.16 | -6.36 | -7.89 | -5.17 | -3.18 | -0.59 | 2.31 | 1.83 | 0.36 | 1.96 | 2.72 | 3.44 | 4.78 | 4.25 | 4.28 | 3.84 | 36.88 | 39.04 | 40.05 | 43.92 | 15.65 | 21.84 | 19.69 | 15.67 | 18.22 | 2.62 | -0.43 | 8.74 | -5.51 |
ROA % |
-43.07 | -13.01 | -22.07 | -25.28 | -20.79 | -26.60 | -27.73 | -21.97 | -16.19 | -15.15 | -11.74 | -7.94 | -2.22 | 5.99 | -24.99 | -24.89 | -27.89 | -35.37 | -6.48 | -0.49 | 2.68 | -12.34 | -13.15 | -17.46 | -18.20 | -4.15 | -3.24 | -3.99 | -2.60 | -1.54 | -0.21 | 1.23 | 1.00 | 0.20 | 1.07 | 1.48 | 1.87 | 2.86 | 2.91 | 3.09 | 2.77 | 25.27 | 26.34 | 26.78 | 29.02 | 8.84 | 11.88 | 10.67 | 8.43 | 8.84 | 1.18 | -0.20 | 3.75 | -2.28 |
ROCE % |
-13.97 | -31.12 | -42.68 | -50.42 | -35.51 | -49.50 | -51.15 | -49.27 | -36.18 | -31.06 | -20.36 | -14.13 | -0.18 | -92.36 | -101.77 | -106.14 | -104.13 | -99.41 | 2.51 | 6.88 | 14.54 | 14.22 | 9.89 | -2.10 | -2.19 | -3.01 | -4.78 | -7.68 | -5.42 | -0.96 | 0.88 | 2.74 | 5.25 | 9.24 | 6.96 | 6.71 | 6.94 | 9.60 | 7.78 | 4.95 | 4.19 | 8.41 | 7.95 | 9.83 | 10.47 | 21.52 | 17.87 | 15.95 | 11.91 | 21.22 | 5.52 | 0.28 | 9.32 | -4.65 |
DSO |
47.6 | 41.8 | 34.7 | 47.3 | - | 39.4 | 38.6 | 58.7 | - | 40.0 | 44.9 | 59.3 | - | 24.2 | 40.4 | 60.2 | 35.8 | 36.9 | 38.0 | 45.6 | 49.4 | 37.0 | 34.3 | 56.8 | 32.8 | 35.4 | 34.6 | 39.2 | - | 31.8 | 31.3 | 28.8 | - | 18.9 | 24.2 | 28.7 | - | 22.3 | 26.4 | 34.0 | - | 28.0 | 26.4 | 31.5 | - | 27.6 | 27.2 | 28.4 | - | 21.6 | 33.0 | 31.3 | - | - |
DIO |
394.6 | 441.0 | 420.7 | 369.9 | - | 126.8 | 156.3 | 255.3 | - | 157.6 | 212.6 | 214.0 | - | 236.4 | 400.9 | 603.0 | - | 317.0 | 289.1 | 313.6 | - | 104.3 | 85.2 | 147.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
274.0 | 208.9 | 89.8 | 178.7 | - | 80.7 | 86.7 | 150.0 | - | 113.1 | 108.7 | 82.6 | - | 93.7 | 183.0 | 455.1 | - | 305.7 | 255.8 | 387.9 | - | 80.8 | 49.6 | 101.2 | - | 63.5 | 63.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
380.8 | - | - | 417.1 | - | 166.2 | 194.9 | 314.0 | - | 197.6 | 257.6 | 273.2 | - | 249.7 | 447.8 | 708.5 | 39.9 | 330.4 | 285.2 | 328.3 | 30.9 | 120.2 | 101.1 | 192.1 | 39.4 | 52.7 | 53.3 | 51.1 | - | 35.1 | 37.4 | 33.0 | - | 19.4 | 25.2 | 29.1 | - | 27.7 | 30.3 | 35.7 | - | 33.1 | 32.3 | 36.3 | - | 31.0 | 31.8 | 31.5 | - | 22.4 | 31.9 | - | - | - |
Cash Conversion Cycle |
223.5 | - | - | 238.5 | - | 85.5 | 108.2 | 164.0 | - | 84.5 | 148.9 | 190.7 | - | 158.6 | 281.2 | 252.5 | 39.9 | 30.4 | 30.2 | -61.2 | 30.9 | -57.0 | -45.7 | 23.6 | 39.4 | -30.6 | -30.9 | 51.1 | - | 35.1 | 37.4 | 33.0 | - | 19.4 | 25.2 | 29.1 | - | 27.7 | 30.3 | 35.7 | - | 33.1 | 32.3 | 36.3 | - | 31.0 | 31.8 | 31.5 | - | 22.4 | 31.9 | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Acorda Therapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Israel
Irlanda
Britain
Canada